Affinity Asset Advisors
NEW YORK, NYfiles as Affinity Asset Advisors, LLC
$2.0bn in 101 US stocks at the end of 30 June 2026. The top 10 are 43.2% of the money. It changed about 22.2% of the portfolio this quarter.
Value
$2.0bn
Stocks
101
Top 10 share
43.2%
Turnover
22.2%
What changed this quarter
New
Bought for the first time this quarter.
- First Tracks BiotherapeuticsTRAX2.0% of the fund
- IDEAYA BiosciencesIDYA0.7% of the fund
- Odyssey TherapeuticsODTX0.7% of the fund
- uniQureQURE0.4% of the fund
- Ascendis Pharma A/SASND0.4% of the fund
- Assembly BiosciencesASMB0.3% of the fund
- Hemab Therapeutics HoldingsCOAG0.3% of the fund
- Research Alliance Corp IIIRACC0.2% of the fund
- Amanat AcquisitionAMAN0.2% of the fund
- BiohavenBHVN0.2% of the fund
- Faeth TherapeuticsFTH0.2% of the fund
- JATT II AcquisitionJATT0.1% of the fund
- Neumora TherapeuticsNMRA<0.1% of the fund
- Amylyx PharmaceuticalsAMLX<0.1% of the fund
- Spruce BiosciencesSPRB<0.1% of the fund
- Eikon TherapeuticsEIKN<0.1% of the fund
- enGene TherapeuticsENGN<0.1% of the fund
- Boundless BioBOLD<0.1% of the fund
Added
Bought more of a stock they already held.
- Roivant SciencesROIV6.6% of the fund+34%
- InsmedINSM3.4% of the fund+35%
- Praxis Precision MedicinesPRAX3.1% of the fund+9%
- Oruka TherapeuticsORKA2.8% of the fund+18%
- Avalo TherapeuticsAVTX2.7% of the fund+116%
- Revolution MedicinesRVMD2.3% of the fund+150%
- Dianthus TherapeuticsDNTH1.9% of the fund+14%
- Sutro BiopharmaSTRO1.9% of the fund+10%
- Lexeo TherapeuticsLXEO1.3% of the fund+15%
- Celldex TherapeuticsCLDX1.3% of the fund+40%
- Belite BIOBLTE1.3% of the fund+154%
- Forte Biosciences1.2% of the fund+13%
- Alto NeuroscienceANRO1.1% of the fund+70%
- Relay TherapeuticsRLAY1.0% of the fund+163%
- Sagimet BiosciencesSGMT1.0% of the fund+188%
- Jade BiosciencesJBIO0.9% of the fund+31%
- Cullinan TherapeuticsCGEM0.8% of the fund+12%
- Perspective TherapeuticsCATX0.7% of the fund+33%
- EquilliumEQ0.7% of the fund+234%
- Establishment Labs HoldingsESTA0.6% of the fund+48%
- Climb BioCLYM0.6% of the fund+39%
- VeradermicsMANE0.6% of the fund+43%
- Taysha Gene TherapiesTSHA0.6% of the fund+75%
- Eupraxia PharmaceuticalsEPRX0.5% of the fund+4%
- ProQR TherapeuticsPRQR0.5% of the fund+126%
Cut
Sold some of their stake.
- Apogee TherapeuticsAPGE6.5% of the fund-23%
- Xenon PharmaceuticalsXENE4.8% of the fund-5%
- Alkermes plc.ALKS2.9% of the fund-17%
- AnaptysbioANAB2.8% of the fund-12%
- CytokineticsCYTK2.3% of the fund-21%
- Abivax SAABVX2.2% of the fund-19%
- Nuvalent1.7% of the fund-8%
- Trevi TherapeuticsTRVI1.7% of the fund-10%
- Ovid TherapeuticsOVID1.4% of the fund-5%
- Enliven TherapeuticsELVN1.3% of the fund-15%
- Madrigal PharmaceuticalsMDGL1.1% of the fund-27%
- Cogent BiosciencesCOGT0.9% of the fund-40%
- Teva Pharmaceutical IndustriesTEVA0.6% of the fund-73%
- Arrowhead PharmaceuticalsARWR0.6% of the fund-25%
- Damora Therapeutics0.5% of the fund-6%
- Zura BioZURA0.4% of the fund-43%
- Tyra BiosciencesTYRA0.3% of the fund-22%
- CRISPR Therapeutics AGCRSP0.3% of the fund-33%
- RezoluteRZLT0.3% of the fund-35%
- ArriVent BioPharmaAVBP0.2% of the fund-29%
- COMPASS PathwaysCMPS0.2% of the fund-73%
- MBX BiosciencesMBX0.2% of the fund-50%
- Karyopharm TherapeuticsKPTI0.2% of the fund-38%
- SpyGlass PharmaSGP0.1% of the fund-47%
- Adlai NortyeANL<0.1% of the fund-7%
Sold out
Sold their entire stake.
- Centessa Pharmaceuticals-100%
- Arcellx-100%
- Terns Pharmaceuticals-100%
- Ascendis Pharma A/SASND-100%
- BridgeBio PharmaBBIO-100%
- Wave Life SciencesWVE-100%
- Engene Holdings-100%
- Corcept TherapeuticsCORT-100%
- Kezar Life Sciences-100%
Holdings
- Apogee TherapeuticsAPGE
- Share
- 6.5%
- Value
- $131m
- Shares
- 987,000
-23%
- Abivax SAABVX
- Share
- 2.2%
- Value
- $44m
- Shares
- 330,000
-19%
- First Tracks BiotherapeuticsTRAX
- Share
- 2.0%
- Value
- $41m
- Shares
- 2,032,012
New
- Nuvalent
- Share
- 1.7%
- Value
- $34m
- Shares
- 275,000
-8%
- Belite BIOBLTE
- Share
- 1.3%
- Value
- $25m
- Shares
- 165,000
+154%
- Forte Biosciences
- Share
- 1.2%
- Value
- $24m
- Shares
- 1,145,391
+13%
- Odyssey TherapeuticsODTX
- Share
- 0.7%
- Value
- $14m
- Shares
- 766,346
New
- Helix Acquisition Corp. IIIHLXC
- Share
- 0.7%
- Value
- $13m
- Shares
- 1,250,000
Held
- Damora Therapeutics
- Share
- 0.5%
- Value
- $11m
- Shares
- 425,000
-6%
- Eupraxia PharmaceuticalsEPRX
- Share
- 0.5%
- Value
- $11m
- Shares
- 1,650,000
+4%
- Generate BiomedicinesGENB
- Share
- 0.3%
- Value
- $7m
- Shares
- 400,000
+14%
- Newamsterdam Pharma CompanyNAMSW
- Share
- 0.3%
- Value
- $5m
- Shares
- 245,000
Held
- Hemab Therapeutics HoldingsCOAG
- Share
- 0.3%
- Value
- $5m
- Shares
- 138,030
New
- Research Alliance Corp IIIRACC
- Share
- 0.2%
- Value
- $4m
- Shares
- 370,000
New
- Amanat AcquisitionAMAN
- Share
- 0.2%
- Value
- $4m
- Shares
- 375,000
New
- Crinetics PharmaceuticalsCRNX
- Share
- 0.1%
- Value
- $3m
- Shares
- 75,000
Held
- Oaktree Acquisition Corp IIIOACCU
- Share
- 0.1%
- Value
- $3m
- Shares
- 250,000
Held
- JATT II AcquisitionJATT
- Share
- 0.1%
- Value
- $2m
- Shares
- 200,000
New
- Adlai NortyeANL
- Share
- <0.1%
- Value
- $2m
- Shares
- 153,847
-7%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Roivant SciencesROIV | 6.6% | $133m | 3,750,000 | +34% |
| Apogee TherapeuticsAPGE | 6.5% | $131m | 987,000 | -23% |
| Spyre TherapeuticsSYRE | 5.6% | $114m | 1,279,134 | Held |
| Xenon PharmaceuticalsXENE | 4.8% | $96m | 1,595,000 | -5% |
| ErascaERAS | 4.8% | $96m | 5,250,000 | Held |
| InsmedINSM | 3.4% | $69m | 650,000 | +35% |
| Praxis Precision MedicinesPRAX | 3.1% | $62m | 185,000 | +9% |
| Alkermes plc.ALKS | 2.9% | $59m | 1,125,000 | -17% |
| Oruka TherapeuticsORKA | 2.8% | $56m | 590,000 | +18% |
| AnaptysbioANAB | 2.8% | $56m | 826,109 | -12% |
| Avalo TherapeuticsAVTX | 2.7% | $54m | 2,900,000 | +116% |
| CytokineticsCYTK | 2.3% | $47m | 550,000 | -21% |
| Revolution MedicinesRVMD | 2.3% | $47m | 250,000 | +150% |
| Abivax SAABVX | 2.2% | $44m | 330,000 | -19% |
| First Tracks BiotherapeuticsTRAX | 2.0% | $41m | 2,032,012 | New |
| Dianthus TherapeuticsDNTH | 1.9% | $39m | 400,000 | +14% |
| Sutro BiopharmaSTRO | 1.9% | $39m | 1,172,487 | +10% |
| Nuvalent | 1.7% | $34m | 275,000 | -8% |
| Trevi TherapeuticsTRVI | 1.7% | $34m | 1,800,172 | -10% |
| Ovid TherapeuticsOVID | 1.4% | $27m | 10,144,562 | -5% |
| Lexeo TherapeuticsLXEO | 1.3% | $27m | 5,807,611 | +15% |
| Celldex TherapeuticsCLDX | 1.3% | $26m | 700,000 | +40% |
| Belite BIOBLTE | 1.3% | $25m | 165,000 | +154% |
| Enliven TherapeuticsELVN | 1.3% | $25m | 500,000 | -15% |
| Forte Biosciences | 1.2% | $24m | 1,145,391 | +13% |
| Nurix TherapeuticsNRIX | 1.2% | $23m | 967,620 | Held |
| Alto NeuroscienceANRO | 1.1% | $22m | 850,000 | +70% |
| Madrigal PharmaceuticalsMDGL | 1.1% | $21m | 40,000 | -27% |
| Protagonist TherapeuticsPTGX | 1.0% | $21m | 172,125 | Held |
| Mineralys TherapeuticsMLYS | 1.0% | $20m | 750,000 | Held |
| Relay TherapeuticsRLAY | 1.0% | $20m | 1,050,000 | +163% |
| Sagimet BiosciencesSGMT | 1.0% | $19m | 2,497,864 | +188% |
| Jade BiosciencesJBIO | 0.9% | $19m | 840,350 | +31% |
| Cogent BiosciencesCOGT | 0.9% | $17m | 450,000 | -40% |
| Travere TherapeuticsTVTX | 0.8% | $17m | 300,000 | Held |
| Cullinan TherapeuticsCGEM | 0.8% | $16m | 875,760 | +12% |
| SavaraSVRA | 0.8% | $15m | 2,512,153 | Held |
| IDEAYA BiosciencesIDYA | 0.7% | $15m | 400,000 | New |
| Perspective TherapeuticsCATX | 0.7% | $14m | 4,214,582 | +33% |
| Odyssey TherapeuticsODTX | 0.7% | $14m | 766,346 | New |
| Helix Acquisition Corp. IIIHLXC | 0.7% | $13m | 1,250,000 | Held |
| EquilliumEQ | 0.7% | $13m | 4,100,000 | +234% |
| Establishment Labs HoldingsESTA | 0.6% | $13m | 148,013 | +48% |
| Climb BioCLYM | 0.6% | $13m | 972,000 | +39% |
| Teva Pharmaceutical IndustriesTEVA | 0.6% | $13m | 374,000 | -73% |
| VeradermicsMANE | 0.6% | $12m | 100,000 | +43% |
| Arrowhead PharmaceuticalsARWR | 0.6% | $12m | 150,000 | -25% |
| Taysha Gene TherapiesTSHA | 0.6% | $12m | 1,750,000 | +75% |
| Damora Therapeutics | 0.5% | $11m | 425,000 | -6% |
| Eupraxia PharmaceuticalsEPRX | 0.5% | $11m | 1,650,000 | +4% |
| Vera TherapeuticsVERA | 0.5% | $11m | 250,000 | Held |
| ProQR TherapeuticsPRQR | 0.5% | $10m | 5,543,936 | +126% |
| NewAmsterdam PharmaNAMS | 0.5% | $9m | 275,000 | Held |
| Korro BioKRRO | 0.5% | $9m | 706,904 | Held |
| Anteris Technologies GlobalAVR | 0.4% | $9m | 912,397 | Held |
| Zura BioZURA | 0.4% | $9m | 1,464,303 | -43% |
| uniQureQURE | 0.4% | $8m | 175,000 | New |
| Ascendis Pharma A/SASND | 0.4% | $8m | 30,000 | New |
| iBioIBIO | 0.3% | $7m | 4,007,881 | +29% |
| Generate BiomedicinesGENB | 0.3% | $7m | 400,000 | +14% |
| Tyra BiosciencesTYRA | 0.3% | $6m | 200,012 | -22% |
| Sol-Gel TechnologiesSLGL | 0.3% | $6m | 84,900 | +143% |
| SAB BiotherapeuticsSABS | 0.3% | $6m | 1,525,000 | +165% |
| MacrogenicsMGNX | 0.3% | $6m | 1,216,606 | +143% |
| CRISPR Therapeutics AGCRSP | 0.3% | $5m | 100,000 | -33% |
| Newamsterdam Pharma CompanyNAMSW | 0.3% | $5m | 245,000 | Held |
| Assembly BiosciencesASMB | 0.3% | $5m | 190,000 | New |
| RezoluteRZLT | 0.3% | $5m | 1,000,000 | -35% |
| Precision BiosciencesDTIL | 0.3% | $5m | 646,576 | +8% |
| Hemab Therapeutics HoldingsCOAG | 0.3% | $5m | 138,030 | New |
| Viridian TherapeuticsVRDN | 0.2% | $5m | 250,000 | Held |
| ArriVent BioPharmaAVBP | 0.2% | $4m | 125,000 | -29% |
| Verrica PharmaceuticalsVRCA | 0.2% | $4m | 707,338 | Held |
| COMPASS PathwaysCMPS | 0.2% | $4m | 301,183 | -73% |
| MBX BiosciencesMBX | 0.2% | $4m | 75,000 | -50% |
| Research Alliance Corp IIIRACC | 0.2% | $4m | 370,000 | New |
| ImmunovantIMVT | 0.2% | $4m | 100,000 | Held |
| Amanat AcquisitionAMAN | 0.2% | $4m | 375,000 | New |
| BiohavenBHVN | 0.2% | $4m | 250,000 | New |
| Faeth TherapeuticsFTH | 0.2% | $4m | 144,404 | New |
| Karyopharm TherapeuticsKPTI | 0.2% | $3m | 312,500 | -38% |
| AlectorALEC | 0.2% | $3m | 1,510,000 | +202% |
| SpyGlass PharmaSGP | 0.1% | $3m | 131,586 | -47% |
| Crinetics PharmaceuticalsCRNX | 0.1% | $3m | 75,000 | Held |
| Oaktree Acquisition Corp IIIOACCU | 0.1% | $3m | 250,000 | Held |
| JATT II AcquisitionJATT | 0.1% | $2m | 200,000 | New |
| Neumora TherapeuticsNMRA | <0.1% | $2m | 1,070,651 | New |
| Amylyx PharmaceuticalsAMLX | <0.1% | $2m | 98,999 | New |
| Adlai NortyeANL | <0.1% | $2m | 153,847 | -7% |
| Spruce BiosciencesSPRB | <0.1% | $2m | 30,000 | New |
| Eikon TherapeuticsEIKN | <0.1% | $1m | 98,001 | New |
| OnKure TherapeuticsOKUR | <0.1% | $1m | 240,963 | Held |
| enGene TherapeuticsENGN | <0.1% | $1m | 600,000 | New |
| X4 PharmaceuticalsXFOR | <0.1% | $677,150 | 145,000 | Held |
| Boundless BioBOLD | <0.1% | $625,000 | 250,000 | New |
| LENZ TherapeuticsLENZ | <0.1% | $568,000 | 100,000 | Held |
| Q32 BioQTTB | <0.1% | $353,879 | 27,777 | Held |
| Orchestra BioMed HoldingsOBIO | <0.1% | $144,121 | 33,400 | -92% |
| NextCureNXTC | <0.1% | $67,136 | 41,960 | -83% |
| Adagio Medical HoldingsADGM | <0.1% | $52,128 | 80,000 | Held |
Showing the largest 100 of 101.
Options (9)
- ModernaMRNA
- Type
- Put
- Value
- $35m
- Contracts
- 500,000
- ModernaMRNA
- Type
- Call
- Value
- $33m
- Contracts
- 475,000
- ARK ETF TRARKG
- Type
- Call
- Value
- $32m
- Contracts
- 750,000
- Eli LillyLLY
- Type
- Call
- Value
- $24m
- Contracts
- 20,000
- OmerosOMER
- Type
- Put
- Value
- $13m
- Contracts
- 1,411,300
- Alkermes plc.ALKS
- Type
- Call
- Value
- $13m
- Contracts
- 250,000
- uniQureQURE
- Type
- Call
- Value
- $9m
- Contracts
- 200,000
- EvommuneEVMN
- Type
- Put
- Value
- $7m
- Contracts
- 500,100
- Summit TherapeuticsSMMT
- Type
- Call
- Value
- $1m
- Contracts
- 100,000
| Company | Type | Value | Contracts |
|---|---|---|---|
| ModernaMRNA | Put | $35m | 500,000 |
| ModernaMRNA | Call | $33m | 475,000 |
| ARK ETF TRARKG | Call | $32m | 750,000 |
| Eli LillyLLY | Call | $24m | 20,000 |
| OmerosOMER | Put | $13m | 1,411,300 |
| Alkermes plc.ALKS | Call | $13m | 250,000 |
| uniQureQURE | Call | $9m | 200,000 |
| EvommuneEVMN | Put | $7m | 500,100 |
| Summit TherapeuticsSMMT | Call | $1m | 100,000 |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 209.8% since 30 June 2025.
Where the money is
Health care91.7%
Financial services1.0%
Other7.4%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.